Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.55 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8277006 | 0.88 | ADAM17 (0.71) | ADAM17ADAM10MMP1MMP2MMP3 | |
| SCHEMBL8221213 | 0.88 | ADAM17 (0.71) | ADAM17ADAM10MMP1MMP2MMP3 | |
| SCHEMBL8273742 | 0.87 | ADAM17 (0.61) | ADAM17 | |
| SCHEMBL8273746 | 0.85 | ADAM17 (0.59) | ADAM17ADAM10MMP1MMP2MMP3 | |
| SCHEMBL8273739 | 0.83 | ADAM17 (0.79) | ADAM17ADAM10MMP2MMP3MMP13 | |
| SCHEMBL8274406 | 0.82 | ADAM17 (0.49) | ADAM17ADAM10MMP1MMP2MMP3 | |
| SCHEMBL8273741 | 0.80 | ADAM17 (0.48) | ADAM17 | |
| SCHEMBL8273740 | 0.79 | ADAM17 (0.52) | ADAM17ADAM10MMP1MMP2MMP3 | |
| SCHEMBL8273582 | 0.78 | ADAM17 (0.47) | ADAM17ADAM10MMP13 | |
| SCHEMBL8275634 | 0.76 | ADAM17 (0.79) | ADAM17ADAM10MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |